Copyright © 2019. Inderes Oy. All rights reserved.
Faron Pharmaceuticals
1333 sijoittajaa seuraa tätä yhtiötä
Yhtiö ei ole seurannassa. Katso kaikki yhtiöt tästä.
OSTO 3.48 ALIN 3.42 VAIHTO (KPL) 38 011
MYYNTI 3.55 YLIN 3.72 VAIHTO (VAL) 0,134 Milj. EUR

Haluaisitko nähdä Inderesin yhtiölle antamat suositukset ja tavoitehinnat?

Onko sinulla jo Inderes -tili? Kirjaudu sisään tästä.

Tulevat tapahtumat

24
Syy
Osavuosikatsaukset

Sisäpiirin kaupat

Nettovaikuttavuus

Faron Pharmaceuticals

Faron Pharmaceuticals

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Clevegen®, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen® has potential as a single-agent therapy or in combination with other immune checkpoint molecules or other cancer standard cares. Traumakine®, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine®. Faron is based in Turku, Finland. Further information is available at www.faron.com.